BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
+5.04%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.97B
AUM Growth
-$106M
(-1.5%)
Cap. Flow
-$278M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
34.81%
Holding
187
New
15
Increased
42
Reduced
87
Closed
11
Top Buys
| 1 |
Revolution Medicines
RVMD
|
$25.6M |
| 2 |
Celldex Therapeutics
CLDX
|
$24.6M |
| 3 |
Exact Sciences
EXAS
|
$12.1M |
| 4 |
Tandem Diabetes Care
TNDM
|
$12M |
| 5 |
Charles River Laboratories
CRL
|
$6.28M |
Top Sells
| 1 |
RDUS
Radius Health, Inc.
RDUS
|
$91.2M |
| 2 |
Sarepta Therapeutics
SRPT
|
$42.4M |
| 3 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$26.3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$20.3M |
| 5 |
Axsome Therapeutics
AXSM
|
$14.3M |
Sector Composition
| 1 | Healthcare | 99.34% |
| 2 | Industrials | 0.59% |
| 3 | Energy | 0.02% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABMD
51
DELISTED
Abiomed Inc
ABMD
| $40.9M | 0.59% |
166,355
-3,154
| -2% | -$775K |
|
|
ACCD
52
DELISTED
Accolade, Inc. Common Stock
ACCD
| $40.8M | 0.59% |
3,571,870
-63,016
| -2% | -$720K |
|
53
Globus Medical
GMED
$8.04B
| $38.6M | 0.55% |
647,163
-9,518
| -1% | -$567K |
|
54
Outset Medical
OM
$233M
| $38.5M | 0.55% |
161,164
+6,049
| +4% | +$1.45M |
|
55
Halozyme
HALO
$8.69B
| $36.8M | 0.53% |
930,500
-40,800
| -4% | -$1.61M |
|
|
56
Exact Sciences
EXAS
$9.76B
| $36.7M | 0.53% |
1,129,653
+371,630
| +49% | +$12.1M |
|
57
Thermo Fisher Scientific
TMO
$183B
| $36.6M | 0.53% |
72,144
+326
| +0.5% | +$165K |
|
58
Omnicell
OMCL
$1.51B
| $36.1M | 0.52% |
414,284
-11,539
| -3% | -$1M |
|
59
Penumbra
PEN
$10.8B
| $36M | 0.52% |
189,774
-2,814
| -1% | -$534K |
|
60
Idexx Laboratories
IDXX
$51.2B
| $35.5M | 0.51% |
108,822
-6,951
| -6% | -$2.26M |
|
61
Pfizer
PFE
$140B
| $33.6M | 0.48% |
767,300
-68,384
| -8% | -$2.99M |
|
62
Pacific Biosciences
PACB
$369M
| $31.6M | 0.45% |
5,439,551
-521,678
| -9% | -$3.03M |
|
63
Harmony Biosciences
HRMY
$2.11B
| $29.1M | 0.42% |
657,188
-44,880
| -6% | -$1.99M |
|
64
IQVIA
IQV
$31B
| $29M | 0.42% |
160,227
-8,371
| -5% | -$1.52M |
|
65
Esperion Therapeutics
ESPR
$488M
| $28.3M | 0.41% |
4,225,264
-10,000
| -0.2% | -$67K |
|
66
Zimmer Biomet
ZBH
$20.8B
| $27.7M | 0.4% |
265,270
-817
| -0.3% | -$85.4K |
|
67
Mersana Therapeutics
MRSN
$34.1M
| $27.6M | 0.4% |
163,304
+7,496
| +5% | +$1.27M |
|
68
Transmedics
TMDX
$3.48B
| $27.3M | 0.39% |
653,814
+73,927
| +13% | +$3.09M |
|
69
Beam Therapeutics
BEAM
$1.84B
| $27.2M | 0.39% |
571,721
-900
| -0.2% | -$42.9K |
|
70
Kezar Life Sciences
KZR
$28.6M
| $26.1M | 0.37% |
303,100
-400
| -0.1% | -$34.4K |
|
71
Veeva Systems
VEEV
$43.9B
| $26M | 0.37% |
157,591
-11,185
| -7% | -$1.84M |
|
72
Legend Biotech
LEGN
$6.41B
| $25.5M | 0.37% |
625,461
-4,978
| -0.8% | -$203K |
|
73
MacroGenics
MGNX
$116M
| $25.3M | 0.36% |
7,325,514
| – | – |
|
74
AtriCure
ATRC
$1.77B
| $25.1M | 0.36% |
642,447
+551
| +0.1% | +$21.5K |
|
75
Castle Biosciences
CSTL
$668M
| $24.6M | 0.35% |
941,871
+812
| +0.1% | +$21.2K |
|